{"id":"standard-aprepitant","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of substance P, a natural substance that causes nausea and vomiting. This is particularly useful in the treatment of chemotherapy-induced nausea and vomiting. By blocking the action of substance P, aprepitant reduces the incidence and severity of nausea and vomiting.","oneSentence":"Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:13.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting"},{"name":"Delayed chemotherapy-induced nausea and vomiting"},{"name":"Postoperative nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT07455955","phase":"PHASE2","title":"Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-06-03","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT07248280","phase":"PHASE3","title":"Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2026-02-27","conditions":"Nausea and Vomiting, Postoperative, Prevention","enrollment":260},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT06740812","phase":"PHASE4","title":"Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Nausea and Vomiting, Nausea, Vomiting","enrollment":212},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT06357234","phase":"PHASE2","title":"Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery","status":"RECRUITING","sponsor":"IWK Health Centre","startDate":"2025-03-17","conditions":"Spinal Fusion, Nausea and Vomiting, Postoperative, Anesthesia","enrollment":100},{"nctId":"NCT05189756","phase":"PHASE4","title":"Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-03-17","conditions":"Postoperative Nausea and Vomiting, Bariatric Surgery","enrollment":71},{"nctId":"NCT04054193","phase":"PHASE4","title":"Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-09","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":103},{"nctId":"NCT02939287","phase":"PHASE3","title":"Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2017-09-23","conditions":"Nausea, Vomiting","enrollment":52},{"nctId":"NCT01186029","phase":"NA","title":"Comparison of Adding EMEND to PONV/PDNV Treatment Regimen","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2011-09-01","conditions":"Postoperative Nausea and Vomiting","enrollment":""},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT06224894","phase":"NA","title":"The Effect of Music Therapy on Nausea, Vomiting and Anxiety Levels in Children","status":"UNKNOWN","sponsor":"Bilecik Seyh Edebali Universitesi","startDate":"2024-02-01","conditions":"Music Therapy, Nausea, Anxiety","enrollment":80},{"nctId":"NCT05792228","phase":"NA","title":"A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-02","conditions":"Squamous Cell Carcinoma of Head and Neck, Chemotherapy Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT03237611","phase":"PHASE2","title":"Low Dose Aprepitant for Patients Receiving Carboplatin","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2018-10-30","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":15},{"nctId":"NCT05772676","phase":"PHASE4","title":"The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting","status":"UNKNOWN","sponsor":"Hospital General Tlahuac","startDate":"2022-12-01","conditions":"Obesity, Nausea and Vomiting, Postoperative","enrollment":400},{"nctId":"NCT04935255","phase":"","title":"Determining the Clinical Relevance of the inTeraction Between AprepitaNt aNd EtoposiDe","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-08-11","conditions":"Testicular Cancer","enrollment":17},{"nctId":"NCT05346731","phase":"PHASE3","title":"Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-04-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":210},{"nctId":"NCT01334086","phase":"PHASE2","title":"Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2011-09","conditions":"Acute Myeloid Leukemia","enrollment":41},{"nctId":"NCT03079219","phase":"PHASE3","title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients","status":"COMPLETED","sponsor":"CCTU","startDate":"2017-03-23","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT01344304","phase":"NA","title":"Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial","status":"COMPLETED","sponsor":"Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group","startDate":"2011-04","conditions":"Colorectal Cancer","enrollment":413},{"nctId":"NCT00588835","phase":"PHASE4","title":"Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2008-03","conditions":"Tumor","enrollment":20},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT02861859","phase":"PHASE3","title":"Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-12","conditions":"Breast Cancer","enrollment":221},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":"Oncology","enrollment":426},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01732458","phase":"PHASE2","title":"A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-12","conditions":"Post-operative Nausea, Post-operative Vomiting","enrollment":229},{"nctId":"NCT00818259","phase":"PHASE1","title":"A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT00781768","phase":"PHASE4","title":"Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea","status":"COMPLETED","sponsor":"Loyola University","startDate":"2003-08","conditions":"Nausea, Vomiting","enrollment":181},{"nctId":"NCT03478605","phase":"PHASE2","title":"Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2018-05-25","conditions":"Emesis, Vomiting, Nausea Post Chemotherapy","enrollment":130},{"nctId":"NCT01450826","phase":"PHASE2","title":"Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide","status":"COMPLETED","sponsor":"Katy Peters","startDate":"2014-06-24","conditions":"Nausea, Vomiting, Glioma","enrollment":136},{"nctId":"NCT01275664","phase":"NA","title":"Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"2011-06","conditions":"Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma","enrollment":4},{"nctId":"NCT00381862","phase":"PHASE2","title":"Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-06","conditions":"Colorectal Cancer, Nausea and Vomiting","enrollment":54},{"nctId":"NCT00952341","phase":"PHASE3","title":"Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08-25","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":421},{"nctId":"NCT01031953","phase":"PHASE1, PHASE2","title":"Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-08","conditions":"Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":34},{"nctId":"NCT00900068","phase":"","title":"Blood Samples From Patients on a Clinical Trial to CINV During HSCT","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-08","conditions":"Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor","enrollment":9},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40},{"nctId":"NCT01432015","phase":"PHASE4","title":"Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Gynecologic Oncology Associates","startDate":"2011-09","conditions":"Ovarian Cancer, Uterine Cancer","enrollment":20},{"nctId":"NCT01913990","phase":"PHASE4","title":"Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2011-09","conditions":"Emesis","enrollment":323},{"nctId":"NCT01490060","phase":"NA","title":"Fosaprepitant in Patients Receiving Ifosfamide-based Regimen","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-05","conditions":"Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy","enrollment":47},{"nctId":"NCT01111942","phase":"EARLY_PHASE1","title":"A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","status":"TERMINATED","sponsor":"Southern Illinois University","startDate":"2010-02","conditions":"Head and Neck Cancer","enrollment":4},{"nctId":"NCT01111851","phase":"PHASE1","title":"Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-04","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":16},{"nctId":"NCT01402024","phase":"PHASE3","title":"Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2011-08","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":96},{"nctId":"NCT00080444","phase":"PHASE3","title":"Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-04","conditions":"Vomiting","enrollment":50},{"nctId":"NCT00651755","phase":"NA","title":"Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-03","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT01101529","phase":"PHASE2","title":"Treatment of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Uppsala University Hospital","startDate":"2010-05","conditions":"Nausea, Vomiting","enrollment":90},{"nctId":"NCT01683552","phase":"PHASE2","title":"Aprepitant in the Management of Biological Therapies-related Severe Pruritus","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2010-09","conditions":"ITCH","enrollment":45},{"nctId":"NCT00571168","phase":"PHASE3","title":"Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2005-07","conditions":"Multiple Myeloma","enrollment":362}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":247,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard: Aprepitant","genericName":"Standard: Aprepitant","companyName":"CCTU","companyId":"cctu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Used for Chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting, Postoperative nausea and vomiting.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}